Regorafenib with Opdivo for colorectal or gastric cancer – pro
A recent study, phase 1 study of 50 patients, of whom 49 were not MSI positive. The cancer is not PDL or MSI +, and current guidelines do not support treatment with an IO inhibitor Opdivo. it included colorectal and gastric cancers and median progression-free survival was 5.6 and 7.9 months in patients with gastric and colorectal cancer, respectively. The 2020 update showed that Median progression free survival (PFS) was 7.8 months in CRC (95% CI, 2.8- NR) and 5.5 months (95% CI, 2.6-10.2 months) in GC. One-year PFS rate was 41.7% in CRC and 22.4% in GC. Median overall survival (OS) was not reached in CRC (95% CI, 9.7-NR) and 12.1 months (95% CI, 5.2-NR) in GC. One-year OS rate was 68% in CRC and 55.3% in GC. The update recommended randomized studies – this is, therefore, still EI treatment at this time.
Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Hirano N, Wakabayashi M, Nomura S, Sato A, Kuwata T, Togashi Y, Nishikawa H, Shitara K.. Aadvanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020 Jun 20;38(18):2053-2061. doi: 10.1200/JCO.19.03296. Epub 2020 Apr 28. PMID: 32343640.
Update in JCO.2020.38.4_suppl.135 Journal of Clinical Oncology 38, no. 4_suppl (February 01, 2020) 135-135.